胸腺肽α1在小儿沙门菌感染性肠炎中的治疗效果

Therapeutic Effect of Thymosinα1 in Salmonella Infectious Enteritis in Children

目的:探讨胸腺肽α1在小儿沙门菌感染性肠炎中的治疗效果。方法:选取2020年1月-2021年12月南方医科大学附属中山市博爱医院250例小儿沙门菌感染性肠炎为观察组,选择同期健康体检者189例为对照组。根据随机数字表法将观察组分为常规组和胸腺肽α1组,各125例。三组患者均进行肠道微生物群落检测,常规组采用敏感抗生素治疗,胸腺肽α1组在常规组治疗基础上给予胸腺肽α1治疗。比较三组肠道微生物菌群。比较常规组及胸腺肽α1组免疫指标及安全性。结果:胸腺肽α1组变形菌门、γ-变形菌纲、芽孢杆菌纲、肠杆菌目、肠杆菌科、链球菌科菌群均低于常规组,厚壁菌门、拟杆菌门、梭菌纲、拟杆菌纲、其他纲、梭菌目、拟杆菌目、其他目、毛螺菌科、拟杆菌科、其他科菌群均高于常规组(P<0.05);常规组肠杆菌科、肠杆菌目、γ-变形菌纲、变形菌门菌群均高于对照组,厚壁菌门、梭菌纲、拟杆菌纲、其他纲、拟杆菌门、梭菌目、拟杆菌目、链球菌科、毛螺菌科、拟杆菌科菌群均低于对照组(P<0.05)。治疗1周后,常规组及胸腺肽α1组CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)水平均得到改善,胸腺肽α1组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均高于常规组,CD8^(+)低于常规组(P<0.05)。常规组及胸腺肽α1组用药期间不良反应发生率比较差异无统计学意义(P>0.05)。结论:胸腺肽α1能降低小儿沙门菌感染性肠炎患者变形菌门、γ-变形菌纲、肠杆菌目、肠杆菌科等菌群数量,调节菌群群落结构,药物安全性较好,值得推广应用。

Objective:To investigate the therapeutic effect of Thymosinα1 in Salmonella infectious enteritis in children.Method:From January 2020 to December 2021,250 children with Salmonella infectious enteritis in Zhongshan Bo’ai Hospital Affiliated to Southern Medical University were selected as the observation group,and 189 healthy physical examiner in the same period were selected as the control group.The observation group was divided into routine group and Thymosinα1 group according to the random number table method,125 cases in each group.Patients in the three groups were tested for intestinal microbiota community,and the routine group was treated with sensitive antibiotics,Thymosinα1 group was given Thymosinα1 treatment on the basis of routine group treatment.The intestinal microbiota flora of the three groups was compared.The immune indexes and safety of routine group and Thymosinα1 group were compared.Result:The flora of Proteobacteria phylum,γ-proteobacteria class,Bacillus class,Enterobacteriaceae order,Enterobacteriaceae family and Streptococci family in thymosinα1 group were lower than those in routine group;Firmicutes phylum,Bacteroidetes phylum,Clostridium class,Bacteroidetes class,other classes,Clostridium order,Bacteroidetes order,other orders,Lachnospiraceae family,Bacteroidetes family and other families were higher than those in the routine group(P<0.05);the bacterial community of Enterobacteriaceae family,Enterobacteriaceae order,γ-Proteobacteria class and Proteobacteria phylum in the routine group were higher than those in the control group,while those of Firmicutes phylum,Clostridium class,Bacteroidetes class,other classes,Bacteroidetes phylum,Clostridium order,Bacteroidetes order,Streptococcusfamily,Lachnospiraceae family and Bacteroidetes family were lower than those in the control group(P<0.05).After 1 week of treatment,the levels of CD3^(+),CD4^(+),CD8^(+)and CD4^(+)/CD8^(+)in the routine group and Thymosinα1 group were improved,and the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the Thymosinα1 group were higher than those in the routine group,and the level of CD8^(+)was lower than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between routine group and thymosinα1 group during medication(P>0.05).Conclusion:Thymosinα1 can reduce the number of Proteobacteria phylum,γ-Proteobacteria class,Enterobacteriaceae order,Enterobacteriaceae family and other bacteria in children infected with Salmonella enteritis patients,and regulate the community structure of the bacteria,and the drug safety is good,worthy of popularization and application.